Search the GHTC website
October 17, 2022

Developing new antimalarial drugs for malaria-free pregnancies

The 2022 World Health Summit, taking place from October 16 to 18, brings together scientific, political, private, and civil society sectors to discuss the achievement of health for all. It is an opportunity to draw attention to the fact that pregnant women are underserved by currently available antimalarial therapies. Medicines for Malaria Venture (MMV), through its Malaria in mothers and babies (MiMBa) strategy, is working with partners to close critical gaps in the availability of well-tolerated malaria prevention and treatment methods for pregnant women to achieve true health for all. 
March 8, 2022

A call to scale up preventive malaria treatment for pregnant women in sub-Saharan Africa

On International Women's Day, Medicines for Malaria Venture calls for sustained action to address biases, discrimination, and inequities that affect women and girls, including their access to malaria prevention and treatment. 

June 21, 2021

Gender issues must not be an afterthought in global health research

A quick glance at the historical trajectory of malaria research reveals that it has been embedded in a larger context of gender bias in medical research. During the clinical development of most new medicines, including antimalarial drugs, pregnant people are actively excluded from trials. Fortunately, there is now growing determination within the malaria community to rectify gender-related data gaps.

June 7, 2019

Saving two lives, not just one: medicines for malaria during pregnancy

An estimated 125 million pregnancies around the world are at risk from malaria annually. For both mother and baby, the disease is potentially life-threatening and babies that do survive are often born with low birth weight, which is associated with negative impact on development.